Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    10891897 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Condition: Refractory Myasthenia Gravis
Intervention: Drug: Rituximab (Rituxan)

Indicates status has not been verified in more than two years